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ABSTRACT
Background: Interstitial lung disease (ILD) is the major cause of mortality in collagen vascular diseases.
However, its pathogenesis still needs to be elucidated.
Methods: To evaluate the alteration of certain proteins in bronchoalveolar lavage fluid (BALF) and clarify the
causative role in the processes of ILD in systemic sclerosis (SSc), we compared a BALF protein profile be-
tween 5 patients with systemic sclerosis with pulmonary fibrosis (SSc-fib+) and 4 patients with systemic sclero-
sis without pulmonary fibrosis (SSc-fib-) using two-dimensional gel electrophoresis (2-DE), and matrix assisted
laser desorptionionization time of flight mass spectrometry (MALDI-TOF MS).
Results:We analyzed spots over the range of 10.1 kDa to 207.4 kDa. SSc-fib+ patients showed increased 3
proteins compared to SSc-fib- including α2-macroglobulin, α1-antitrypsin, and pulmonary surfactant protein A
and decreased 2 proteins including α2 heat shock protein (HSP) and glutathione S-transferase (GST) com-
pared to SSc-fib- patients.
Conclusions: In conclusion, we identified several interesting proteins that might have roles in ILD of SSc pa-
tients. Further studies are warranted to clarify the role of these proteins in the processes of pulmonary fibrosis
in SSc.
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INTRODUCTION
Systemic sclerosis (SSc) is a disease of unknown ori-
gin characterized by excessive deposition of collagen
and other extracellular matrix protein in skin and
multiple internal organs. About 70% of SSc patients
have abnormalities in pulmonary functions, and inter-
stitial lung disease (ILD) is the main cause of mortal-
ity in this population because no reliable ameliorating
treatment is available for such involvement.1 How-
ever, the mechanisms involved in the severe and pro-
gressive pulmonary fibrosis remain unknown. As
shown by the previous studies, nonspecific interstitial
pneumonia (NSIP) pattern is the most frequent histo-
pathologic pattern in ILD of SSc (SSc-ILD). NSIP pat-
tern was diagnosed in 78% with SSc-ILD, while usual
interstitial pneumonia (UIP) pattern was diagnosed in
7.5%.2
Major component of proteins in bronchoalveolar
lavage fluid (BALF) are proteins derived from
plasma. These proteins include α1-antitrypsin, α2-
macroglobulin, apolipoprotein A1, α2-microglobulin,
ceruloplasmin, complement factor 3 and 4, immuno-
globulins and so on.3 Many species of proteins were
detected by differential proteomics analysis of BALF
in ILD. These include immuno-inflammatory media-
tors, oxidantantioxidant balance, proteaseantipro-
tease balance, cytoskeletal, heat shock, coagulation
system, calcium binding, lipid binding, and unknown
function.4 Proteomics analysis of BALF of interstitial
lung disease was started from BALF of sarcoidosis,
and hypersensitivity pneumonitis.5,6 BALF is now the
common way of sampling the components of the epi-
thelial lining fluid and the most faithful reflect of the
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protein composition of the pulmonary airway. Few
analyses were reported about BALF of interstitial
lung disease with collagen vascular diseases. Eleven
proteins (from 16.3 kDa to 69.8 kDa) were shown to
be significantly different between SSc with pulmonary
fibrosis (SSc-fib+) and SSc without pulmonary fibro-
sis (SSc-fib-) in the previous study.7
Aim of this study is to evaluate the alterations of
the BALF proteins in comparison with the detected
proteins in the previous studies and clarify the role of
the proteins in the processes of pulmonary fibrosis in
SSc.
METHODS
PATIENTS SELECTION
BALF samples were obtained from SSc patients be-
tween April 2004 and March 2007. The preliminary
criteria for disease classification American College of
Rheumatology were used to define SSc.8 Out of nine
SSc patients the 5 patients with pulmonary fibrosis
(SSc-fib+) and the 4 patients without pulmonary fibro-
sis (SSc-fib-), were examined in this study. SSc-fib- pa-
tients included 2 male and 2 female patients and SSc-
fib+ patients included 2 male and 3 female. The diag-
nosis of SSc-associated pulmonary fibrosis was based
on clinical, functional and radiographic signs. In all
cases, carbon monoxide transfer, forced vital capac-
ity, chest radiography were evaluated. Patients were
given informed consent for bronchoscopy, and none
were treated with prednisolone nor other immuno-
suppressive agents at the time of enrollment. The
study conformed to the declaration of Helsinki and
was approved by the internal review board of our in-
stitution. Written informed consent was obtained for
each subject.
BROCHOALVEOLAR LAVAGE
Bronchoalveolar lavage (BAL) was performed as pre-
viously described using three 50 ml aliquots of sterile
0.9% saline.9 The cellular composition of the BAL
fluid (BALF) was determined using a cytospun smear
with Wright stain by counting 200 cells. Lymphocyte
phenotypes were analysed by flow cytometry with
monoclonal antibodies for CD4 and CD8.
TWO DIMENSIONAL GEL ELECTROPHORESIS
Two-dimensional (2-D) gel electrophoresis was per-
formed as previously described.7 Shortly, BALF sam-
ples were freeze-dried and concentrated by acetone
precipitation. In each analytical experiment, the same
amount of samples (54 μl) were loaded on immobi-
lized pH gradient (IPG) strips (pH 3 to 10,18 cm; GE
healthcare, Sweden) which were concentrated by
acetone and swollen in 8M urea, 4% CHAPS, 65mM
dithioerythritol, 0.1M acetic acid and pharmalyte (pH
3 to 10 for IEF; GE healthcare) and a trace of bromo-
phenol blue. Rehydration was performed in the strip
holder of the IPG-IEF CoolPhoreStar system
(Anatech, Japan) at 20℃ and isoelectrofocusing was
terminated at 47 kV. The IPG strips were equilibrated
first for 30 minutes in the ureaSDSTris buffer, and
then in the same buffer containing 2.5% iodoacet-
amide. The second-dimensional run was performed
on 10% polyacrylamide linear gradient gels with a
constant current of 20 to 30 mAgel at 20℃, until the
dye front reached the bottom of the gel. Gels were
stained with SYPRO Ruby Protein Gel Stain (Molecu-
lar Probes, USA).
EVALUATION AND IDENTIFICATION OF PRO-
TEINS
The gels are scanned using FluoroPhoreStar 3000
(Anatech) and analyzed using Progenesis Same Spots
(Nonlinear Dynamics Ltd, UK) to create a reference
map for each patient group and to detect differentially
expressed protein spot in SSc-fib+ patients compared
with SSc-fib- patients. The software established the
reference map by taking into account only the spots,
which were consistently expressed in each patient of
the same group. The differences between two groups
were confirmed by analyzing the spot quantities of
pooled samples of SSc-fib+ or SSc-fib-. Non-matching
spots or the spots differed 1.5 folds higher or lower in
quantity were regarded as differentially expressed in
SSc-fib+ patients compared with SSc-fib- patients.
Then we analyze BALF samples of individual be-
tween two groups to verify these results.
Proteins were identified by comparing the BALF
maps, such as the SWISS-2D PAGE human plasma
map and published BALF maps, or matrix-assisted la-
ser desorptionionization time-of-flight mass spec-
trometer (MALDI-TOF MS) as follows. The selected
spots, picked up from Coomassie-stained gels, were
analyzed in Ettan MALDI-TOF Pro mass spectrome-
ter (Amersham Biosciences, USA) at the Cellular and
Proteome Research Laboratory of Tokyo Medical and
Dental University, equipped with a reflectron ana-
lyzer and used in delayed extraction mode. Mass
spectra was used for database searching with MAS-
COT peptide fingerprinting search program (Matrix
Science, USA).
STATISTICAL METHODS
All data were described as mean ± standard error of
the mean (SEM). The Mann-Whitney method was
used for each statistic analysis. P < 0.05 were consid-
ered as statistical significance. Analyses were per-
formed with Stat View 5.0 (Abacus Concept, USA).
RESULTS
Proteome analysis of the individual BALF was per-
formed on 9 SSc patients, including 5 SSc-fib+ and 4
SSc-fib-. Patients’ characteristics were shown in Table
1. No microbiological or clinical evidence of bacterial
or fungal infections were found in all patients. SSc-
fib+ patients showed a significant increase in KL-6
Proteomics of BAL in Systemic Sclerosis
Allergology International Vol 59, No4, 2010 www.jsaweb.jp 411
Table 1 Clinical, immunological and functional characteris-
tics
p valueSSc fib-SSc fib+Parameter
-45number of
patients
0.981 63.5 ± 4.5  63.4 ± 2.0age
NS2/22/3male/female
0.792  9.0 ± 9.0  12.2 ± 7.6smoking
(pack year)
0.323  0.2 ± 0.1   0.6 ± 0.3CRP (mg/dl)
0.570208.2 ± 22.0 228.2 ± 24.9LDH (IU/l)
0.453546.7 ± 375.5 304.0 ± 96.0ANA
0.405  1.3 ± 1.3  15.8 ± 12.1Scl-70
0.028561.3 ± 257.51459.4 ± 197.4KL-6 (U/ml)
0.220135.0 ± 85.4 215.7 ± 62.9SP-D (ng/ml)
0.512 58.2 ± 21.6  93.9 ± 36.7SP-A (ng/ml)
0.111 96.2 ± 13.1  73.1 ± 4.7%VC (%)
0.448 82.7 ± 1.1  81.2 ± 1.3%FEV1.0 (%)
0.473 67.8 ± 12.0  56.9 ± 8.4%DLco (%)
Results were shown as mean ± SEM. SSc-fib+, systemic sclero-
sis patients with pulmonary fibrosis; SSc-fib-, systemic sclerosis 
patients without pulmonary fibrosis; ANA, anti nuclear antibody; 
Scl-70, anti scleroderma antibody; KL-6, sialylated carbohydrate 
antigen; SP-A, pulmonary surfactant protein-A; SP-D, pulmonary 
surfactant protein-D; %VC, percentage of volume capacity; 
%FEV1.0, percentage of forced expiratory volume in one second; 
%DLco, percentage of difusing capacity for carbon monoxide.
Table 2 Bronchoalveolar lavage fluid profiles
p valueSSc-fib-SSc-fib+
-45number of patients
0.90628.0 ± 14.026.0 ± 6.0total cel counts (×106)
0.68867.7 ± 7.8 63.7 ± 4.1macrophages (%)
0.0753.3 ± 1.413.1 ± 5.1neutrophils (%)
0.0571.4 ± 0.4 5.0 ± 1.0eosinophils (%)
0.41527.6 ± 8.1 18.1 ± 7.4lymphocytes (%)
0.0464.6 ± 1.5 1.4 ± 0.4CD4+/CD8+ ratio
Results were shown as mean ± SEM. SSc-fib+, systemic sclero-
sis patients with pulmonary fibrosis; SSc-fib-, systemic sclerosis 
patients without pulmonary fibrosis.
and tended to be decreased in vital capacity and dif-
fusing capacity for carbon monoxide compared to
SSc-fib- patients. This tendency of a decrease was as-
sociated with abnormal chest radiograph and the
presence of significant fibrosis on the HRCT. SSc-fib-
patients revealed no evidence of lung involvement
neither on the lung function tests nor by radiological
findings. The mean recovery rates of BALF in SSc-
fib+ and SSc-fib- patients were 62.7% (range; 59.4% to
64.2%) and 68.5% (range; 63.3% to 70.9%), respectively.
In BALF profiles, no significant difference was ob-
served in total BAL cell counts, the percentage of
macrophages, neutrophils, eosinophils and lympho-
cytes between two groups were shown in Table 2.
The ratio of CD4+ to CD8+ ratio was significantly
higher in SSc-fib- patients than SSc-fib+ patients.
We analyzed the whole protein profiles of pooled
BALF from SSc-fib+ and SSc-fib- by two-dimensional
gel electrophoresis to evaluate the difference of pro-
teins between two groups. Total numbers of spots on
gels of pooled BALF from SSc-fib+ and SSc-fib- was
526 spots and 427 spots, respectively. Then we identi-
fied 41 species of proteins using MALDI-TOF MS
andor gel matching (GM) with 2-D gel electrophore-
sis database from Swiss-PROT (Fig. 1a, Table 3). In
pooled BALF samples of SSc-fib+, we found 5 pro-
teins including α2 macroglobulin, α2 antiplasmin, α1
antitrypsin, immunoglobulin heavy chain γ, and pul-
monary surfactant protein A that were one and a half
times as much as that of the corresponding proteins
in SSc-fib- (Table 4). In comparison of each BALF
sample of the individual patients, α1 antitrypsin, pul-
monary surfactant protein A, and α2 macroglobulin
were significantly increased in SSc-fib+ (Table 5).
In pooled BALF samples of SSc-fib+, we found 9
proteins including immunoglobulin heavy chain α,
liver type fatty acid protein (L-FABP), immunoglobu-
lin J chain α1 antichymotrypsin, haptoglobulin heavy
chain α, α2 heat shock protein (HSP), hemopexin,
and glutathione S-transferase (GST) that were lower
by two-thirds than that of the corresponding proteins
in SSc-fib- (Table 6). In comparison of each BALF
sample of the individual patients α2 HS glycoprotein
and glutathione S-transferase were significantly in-
creased in SSc-fib- (Table 7).
DISCUSSION
We identified 5 proteins whose quantity was different
between SSc-fib- and SSc-fib+. In the recent study,
Fietta et al. reported that α1-acid glycoprotein, albu-
min, cytohesin-2, mitochondrial DNA topoisomerase
1, Cu-Zn superoxide dismutase, calgranulin B,
haptoglobin-α, GST and cystein SN were significantly
different between SSc-fib- and SSc-fib+.7 Those pro-
teins were picked up surveying the protein from 16.3
kDa to 69.8 kDa of low molecular weight. By con-
trast, we identified 5 species of proteins surveying the
wider range of 10.4 kDa to 207.4 kDa that were sig-
nificantly different between SSc-fib- and SSc-fib+ by
MALDI-TOF MS and GM, with a reference of data-
base from Swiss-PROT. Comparison of BALF protein
expression in both the Fietta’s and the present study
was demonstrated in Table 8.
In patients’ characteristics, SSc-fib+ patients showed
an increase of the level of KL-6 and tended to be de-
creased in vital capacity and diffusing capacity, which
may relate to the lung fibrosis. In BALF profiles,
there was no significant difference in total BAL cell
number, the numbers of macrophages, and lympho-
cytes between two groups. The number of neutro-
phils and eosinophils were tended to be higher in
Shirahama R et al.
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a
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Fig. 1 2-DE of BALF from SSc-fib- patient (a), performed using a nonlinear im-
munobiline gradient 4-7, IPG strip folowed by 9-16% SDS PAGE. Proteins were 
detected by SYPRO-Ruby. Numbers indicate proteins and are listed in Table 3. 
The 2-DE paterns of BALF from SSc-fib- patient (b) and SSc-fib+ (c). 
SSc-fib+ patients almost in line with the Fietta’s study.
Whereas, the number of lymphocytes showed no dif-
ference between two groups although Fietta et al.
found a difference.7 The ratio of CD4+ to CD8+ in SSc-
fib- was higher than that in SSc-fib+. It could be due
to increased levels of CD4+ or decreased levels of
CD8+ cells. Wallace et al. suggest an inhibitory effect
of CD4+ T cells on fibroblast function,9 Whereas, Mu-
rayama et al. suggest a possible role of fibrogensis in
the lungs by CD4+ T cells.10 These lines indicate that
the role of the CD4+ T cells might be controversial.
For CD8+ T cells, Rottoli et al. showed CD8+ lympho-
cytes in SSc-fib+ could promote pulmonary fibrosis.11
In comparison of each BALF samples, we identified
3 species of proteins whose quantity of SSc-fib+ is
higher by two-thirds than that of SSc-fib- including
α1-antitrypsin, α2-macroglobulin, and pulmonary sur-
factant protein A (SP-A). Those proteins were
thought to relate to the main mechanism driving alve-
olitis in SSc patients.2 According to the previous re-
port, an accumulation of many plasma proteins was
observed in BALF from SSc-fib+. In this study, we
found an increase in α1-antitrypsin and α2-
macroglobulin in BALF from SSc-fib+. Concerning
these proteins, the levels of α1-antitrypsin and α2-
macroglobulin in BALF of sarcoidosis were higher
than those of IPF patients.5 And the level of α1-
antitrypsin in BALF from SSc fib+ was higher than
that of IPF patients.5,12,13 The increase in these pro-
teins in BALF may result from the activation of im-
Proteomics of BAL in Systemic Sclerosis
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Table 3 BALF protein porfiles identified in SSc-fib+ pa-
tients and SSc-fib- patients
Identification
methodACProtein
Protein
No.
GMP-01023α2 macroglobulin1
GM, MSP-00450ceruloplasmin2
GM, MSP-99003immunoglobulin A S-chain3
GMP-00751complement factor B4
GM, MSP-04217α1 B-glycoprotein5
GM, MSP-02790hemopexin6
GMP-00751complement factor B7
GM, MSP-02787transferin8
GMP-01024complement C3 β9
GM, MSP-02768albumin10
GM, MSP-08697α2 antiplasmin11
GMP-99002immunoglobulin heavy chain α12
GM, MSP-01008antithrombin II13
GM, MSP-02774vitamin D-binding protein14
GM, MSP-01009α1 antitrypsin15
GM, MSP-01011α1 antichymotrypsin16
GM, MSP-02765α2 heat shock protein17
GMP-02679fibrinogen γ, α chain18
GMP-99006immunoglobulin heavy chain γ19
undetermined20
MSP-38593Tol-like receptor 121
GMP-02763orosomucoid 122
GMP-00737haptoglobin β23
MSZinc finger protein GLIS124
MSZinc α-2-glycoprotein25
MStransmembrane protein26
GMP-10909clusterin27
MSP-99009immunoglobulin heavy chain μ28
MS, GMP-07714pulmonary surfactant protein A29
undetermined30
GMP-99007immunoglobulin heavy
chain κ, γ
31
MSP-09211glutathione S-transferase32
GMP-02647apolipoprotein A-133
GMP-02753serum retinol binding protein34
GM, MSP-02766transthyretin35
GMP-30049cytidylate kinase36
GM, MSP-02768albumin fragment37
GMP-01591immunoglobulin J chain38
GMP-07148liver type faty acid binding
protein
39
GMP-02023hemoglobulin β chain40
GMP-01037cystain SN41
Protein No.: Refer to the annotations in Fig. 1. BALF, bronchoal-
veolar lavage fluid; SSc-fib+, systemic sclerosis patients with pul-
monary fibrosis; SSc-fib-, systemic sclerosis patients without 
pulmonary fibrosis; AC, accession number from the SWISS-
PROT database; MS, MALDI-TOF MS; GM, Gel matching with 
two dimensional gel electrophoresis database from Swiss-PROT.
Table 4 Comparison of pooled BALF samples between 
SSc-fib+ patients and SSc-fib- patients (SSc-fib+/SSc-fib-
>1.5)
pooled SSc-fib+/
pooled SSc-fib-
MW
(kDa)Protein
1.64207.4α2 macroglobulin
2.77 65.6α2 antiplasmin
4.06 51.0immnunoglobulin heavy chain γ
1.83 46.9α1 antitrypsin
2.03 26.7pulmonary surfactant protein A
SSc-fib+, systemic sclerosis patients with pulmonary fibrosis; 
SSc-fib-, systemic sclerosis patients without pulmonary fibrosis; 
pooled SSc-fib+, pooled samples of BALF from 5 SSc-fib+ pa-
tients; pooled SSc-fib-, pooled samples of BALF from 4 SSc-fib+ 
patients.
Table 5 Comparison of each BALF sample of the individu-
als between SSc-fib+ patients (n = 5) and SSc-fib- patients 
(n = 4)
p value
Spot
quantity
values of
SSc-fib-
Spot
quantity
values of
SSc-fib+
MW
(kDa)Protein
<0.051.2 ± 1.06.3 ± 1.6207.4α2 macroglobulin
0.295.6 ± 1.917.5 ± 11.7 65.6α2 antiplasmin
0.134.9 ± 2.416.7 ± 7.4  51.0immnunoglobulin 
heavy chain γ
<0.054.1 ± 1.818.2 ± 6.1  46.9α1 antitrypsin
<0.055.9 ± 3.125.5 ± 6.6  26.7pulmonary surfac-
tant protein A
Results were shown as mean ± SEM. SSc-fib+, systemic sclero-
sis patients with pulmonary fibrosis; SSc-fib-, systemic sclerosis 
patients without pulmonary fibrosis.
mune and inflammatory cells within the lung. These
cells may damage the pulmonary tissue, in particular
the alveolar-capillary barrier, leading to an impair-
ment of its barrier function followed by increased per-
meability to proteins.
In this study, we found an increase of SP-A in
BALF of SSc-ILD+. The increase of SP-A in BALF
may result from enhanced synthesis andor release
by secreting cells or from impaired clearance by al-
veolar macrophages, mucociliary transport, degrada-
tion, and absorption into the bloodstream.1 SP-A is
produced by several cell types, including the type II
alveolar epithelial cells in the lung, and secreted into
the lung alveolar space. SP-A plays a role in inflamma-
tion by regulating cytokines, such as tumor necrosis
factor (TNF-α) and interleukin 8 (IL-8) which are pro-
duced by macrophages. Modification of surfactant
proteins was recently analyzed by high-solution
Fourier transform ion cyclotron resonance mass
spectrometry (MALDI-FTICR) MS in BALF from pa-
tients with cystic fibrosis.14,15 SP-A has important
Shirahama R et al.
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Table 6 Comparison of pooled BALF samples between 
SSc-fib+ patients and SSc-fib- patients (SSc-fib+/SSc-fib-
<0.67)
Pooled SSc-fib+/
pooled SSc-fib-
MW
(kDa)Protein
0.31123.0ceruroplasmin
0.2362.0immunoglobulin heavy chain α
0.2356.7α1 antichymotrypsin
0.3052.4hemopexin
0.2840.3haptoglobulin β
0.2725.8glutathione S-transferase
0.2623.9immunoglobulin J chain
0.0013.6α2 heat shock protein
0.1010.0liver type faty acid binding protein
SSc-fib+, systemic sclerosis patients with pulmonary fibrosis; 
SSc-fib-, systemic sclerosis patients without pulmonary fibrosis; 
pooled SSc-fib+, pooled samples of BALF from 5 SSc-fib+ pa-
tients; pooled SSc-fib-, pooled samples of BALF from 4 SSc-fib+ 
patients.
Table 7 Comparison of each BALF sample of the individu-
als between SSc-fib+ patients (n = 5) and SSc-fib- patients 
(n = 4)
p value
Spot
quantity
values of
SSc-fib-
Spot
quantity
values of
SSc-fib+
MW
(kDa)Protein
0.16 7.7 ± 3.8 2.4 ± 2.0123.0ceruroplasmin
0.4326.0 ± 8.5 9.2 ± 2.862.0immunoglobulin 
heavy chain α
0.4310.2 ± 7.7 4.9 ± 2.056.7α1 antichymotrypsin
0.3126.2 ± 14.710.7 ± 6.752.4hemopexin
0.2548.8 ± 23.218.7 ± 12.740.3haptoglobulin β
<0.0564.6 ± 22.3 6.0 ± 4.525.8glutathione
S-transferase
0.43 9.8 ± 8.6 3.5 ± 2.923.9Immunoglobulin
J chain
<0.05 6.2 ± 3.6 0.0 ± 0.013.6α2 heat shock
protein
0.24 7.7 ± 3.8 2.4 ± 2.010.0liver type faty
acid protein
Results were shown as mean ± SEM. SSc-fib+, systemic sclero-
sis patients with pulmonary fibrosis; SSc-fib-, systemic sclerosis 
patients without pulmonary fibrosis.
Table 8 Comparison of BALF proteomics between the Fi-
eta’ sand present study
Present
study
Fieta
et al.
MW
kDaProtein
N/A↑23.5α1-acid glycoprotein
-↑69.4albumin
N/A↑46.5cytohesin-2
N/A↑69.8mitochondrial DNA topoisomerase 1
N/A↓15.8Cu-Zn superoxide dismutase
N/A↓13.2calgranulin B
-↓15.9haptoglobin-α
N/A↓16.3cystein SN
↑N/A207.4α2 macroglobulin
↑N/A46.9α1 antitrypsin
↑N/A26.7pulmonary surfactant protein A
↓↓25.8glutathione S-transferase
↓N/A13.6α2 heat shock protein
↑ , increased in BALF of SSc-fib+; ↓ , decreased in BALF of 
SSc-fib+; -, unchanged between SSc+ and SSc-fib-; N/A, not 
available.
functions for the immunological surveillance of the
lung and has been shown to undergo several struc-
tural modifications of pathophysiological relevance in
lung fibrosis.16,17 In addition, SP-A was used as the
disease marker of the lung fibrosis.
We identified 2 proteins whose quantity of SSc-fib+
is lower by two-thirds than that of SSc-fib- including
α-2 HSP and glutathione S-transferase (GST). HSP is
induced by the various stresses and is involved in the
synthesis, conveyance and disassembly of the protein
inside the cell as a molecular chaperon.18 The cytoki-
nes, TNF-α, IL-6 and IL-8 are induced by HSP. In our
study, the level of HSP was lower in BALF of SSc-fib+
implicating the impaired protection against the lung
injury.
Recently, Fietta et al. reported that the levels of
GST and S-O-D (SOD) in BALF of SSc-fib- patients
are higher than those of SSc-fib+ patients.6 GST is an
anti-oxidation to detoxify toxic hydroxynonenal in-
duced by the lipid peroxidizing reaction. GST is
known to be protective against the injury. In our
study, the lower level of GST of SSc-fib+ is in line with
these findings suggesting that GST has the key pro-
tective role against oxidant-induced damage and fi-
broproliferation. Oxidative damage to proteins may
be the direct result of reactive oxygennitrogen spe-
cies or an indirect effect of secondary products of oxi-
dative stress.19 Formation of carbonyl groups is the
most widely studied as oxidative stress-induced modi-
fication of proteins and regarded as a biomarker of
oxidative stress and is used to quantify oxidative dam-
age to polypeptide chains.20,21 Magi et al. showed that
carbonylated proteins, hemopexin, GST and ceru-
loplasmin were higher in BALF of patients with IPF
than in BALF of SSc-ILD, sarcoidosis and healthy
controls.10 The oxidative stress may be important in
the pathogenesis of lung damage and in the develop-
ment of lung fibrosis.22 GST and superoxide dismu-
tase (SODs) may have the key protective role in the
lung.
There are several limitations in this study. First, it
is not clear whether the protein profiles in this study
are specific for ILD in SSc or universal in most fi-
brotic lung disease. We should conduct BALF pro-
teomics in other diseases such as idiopathic intersti-
tial pneumonias, rheumatoid arthritis, and chronic
Proteomics of BAL in Systemic Sclerosis
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hypersensitivity pneumonitis in the next study. Sec-
ond, it is not clear that the alternation of protein ex-
pressions is systematic or local event in the lungs.
Since we have no comparative data between periph-
eral blood and BALF, this problem could not be con-
cluded in this paper. Finally, minute fibrotic cases
might be included in SSc-fib- group, because high
resolution computed tomography (HRCT) was not
applied in this study. In the diagnosis of SSc-fib+, we
performed not only chest radiography but also pul-
monary function tests including diffusing capacity.
Therefore, most cases of lung fibrosis should be cor-
rectly evaluated.
In conclusion, we identified several interesting pro-
teins that might have roles in ILD of SSc patients.
Further studies are warranted to clarify the role of
proteins in the processing of pulmonary fibrosis in
SSc.
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